Data on Allergan’s Rapastinel and NRX-1074 (AGN-241660) presented at the Society for …

DUBLIN, Nov. 4, 2015 /PRNewswire/ — Allergan plc. (NYSE: AGN), a leading global pharmaceutical company today announced that 6 poster presentations for two investigational medications Rapastinel (GLYX-13 and NRX-1074 were presented at the Society for Neuroscience (SfN) Annual Meeting in Chicago, October 17 – 21, 2015. Logo – http://photos.prnewswire.com/prnh/20150612/222796LOGOThe titles of the poster presentations were as follows:About rapastinel (GLYX-13) and NRX-1074 (AGN-241660)Rapastinel (GLYX-13) is an investigational intravenous formulation of a novel NMDA receptor partial agonist, which is being evaluated for adjunctive treatment of MDD, and has shown a rapid onset of antidepressant efficacy 1 day after a single dose in a Phase 2 clinical trial of patients with MDD who had an inadequate response to one or more antidepressants. No psychotomimetic or hallucinogenic side effects were observed with rapastinel. A series of Phase…


Link to Full Article: Data on Allergan’s Rapastinel and NRX-1074 (AGN-241660) presented at the Society for …

Pin It on Pinterest

Share This

Join Our Newsletter

Sign up to our mailing list to receive the latest news and updates about homeAI.info and the Informed.AI Network of AI related websites which includes Events.AI, Neurons.AI, Awards.AI, and Vocation.AI

You have Successfully Subscribed!